Last €4.26 EUR
Change Today +0.09 / 2.16%
Volume 6.6K
ALTER On Other Exchanges
EN Paris
As of 10:59 AM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

theradiag (ALTER) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/27/14 - €9.30
52 Week Low
12/13/13 - €3.18
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for THERADIAG (ALTER)

Related News

No related news articles were found.

theradiag (ALTER) Related Businessweek News

No Related Businessweek News Found

theradiag (ALTER) Details

Theradiag SA develops, produces, and markets in vitro diagnostics products in France and internationally. It offers auto-immunity products, such as FIDIS kits that allow detection of multiple analytes from the same sample in a single assay; immunofluorescence tests to screen and identify the auto-antibodies; ELISA tests for performing various tests on the same plate; Chorus systems that are compact multi-parametric analyzers; and immunoblot tests, which allow simultaneous detection of antibodies. The company also provides genetic tests comprising AmplideX products line for the diagnosis of the Fragile X syndrome; xTAG Gastrointestinal Pathogens Panel kits for identifying various gastrointestinal pathogens; xTAG Respiratory Viral Panel kits for identification of common respiratory viruses; and BCR/ABL1 Quant tests that are in vitro diagnostic products, as well as Signature kits. In addition, it offers CLA Optigen 30, an in vitro test for the diagnosis of allergy conditions; a panel of reagents for identifying the type of infectious diseases, such as bacteriology, virology, and parasitology; and Immunochromatographic rapid tests for the detection of drugs. Further, the company provides SQA-V system, a semen analyzer; V-Sperm for loading results, pictures, and videos to the computer; OCTEIA 25-Hydroxy Vitamin D kit intended to assay 25-Hydroxy vitamin D and other hydroxylated metabolites present in human serum or plasma; and Serum CrossLaps ELISA kits for the immunoenzyme assay of a specific C-terminal sequence for type I collagen in human serum and plasma, as well as CER F 820001F for analyzing small amounts of hemoglobin in feces. Additionally, it offers a range of instruments, including CARIS, e-Robot, FIDIS, and Chorus instruments for diagnosing auto-immunity and infectious diseases. The company also offers Lisa-Tracker kits for monitoring the treatment of patients treated by anti-TNFa. The company was founded in 1986 and is based in Marne-la-Vallée, France.

51 Employees
Last Reported Date: 03/21/14
Founded in 1986

theradiag (ALTER) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

theradiag (ALTER) Key Developments

TheraDiag Enhances its Oncology Offer with an 8th Test in its Lisa-Tracker Theranostic Range

TheraDiag announced that its Lisa-Tracker range has been further expanded, with an 8th test receiving CE marking in oncology. With the monitoring of the drug and of the anti-drug antibodies, this new test could optimize the treatment of patients on Avastin (bevacizumab molecule). Avastin is the only anti-angiogenic therapy available for treating patients with advanced breast, colon, lung, kidney or ovarian cancer, which are responsible for more than 2.5 million deaths every year. This kit, developed by Theradiag, is the Lisa-Tracker range's second test in oncology and will soon be marketed worldwide. It meets a major need from practitioners, with more than a million patients currently being treated with Avastin.

Theradiag Signs a Fourth microRNA Partnership Agreement with CNRS

Theradiag has signed a fourth research partnership agreement in microRNAs with the French National Center for Scientific Research (CNRS) /the Institute of Molecular Genetics of Montpellier (IGMM) and the University of Montpellier (UM1 and 2) for the development of diagnostics and theranostics tools in Rheumatoid Arthritis (RA). The purpose of this new development program is to identify, on a cohort of 100 patients, microRNA signatures which would improve diagnosis of RA, allow for analysis of disease-activity and severity parameters, and most importantly, provide prognosis information regarding response to treatment. These findings could be the subject of a joint patent application by Theradiag and CNRS. With this new development, Theradiag significantly strengthens its positioning in the auto-immune diseases segment, and should offer, in the near future, a complete diagnostics and theranostics portfolio in RA including: Disease diagnosis (available FIDISTM product range and microRNA test under development); Disease monitoring (microRNA test under development); Monitoring of biotherapies for the disease (available LISA-TRACKER portfolio); Identification of treatment response prognosis factors (microRNA test under development).

Theradiag Unveils Theralis, a New Automated Solution

THERADIAG unveiled Theralis(R), its new automated solution for auto-immune diseases diagnostics, at the International Auto-immunity Congress in Nice, France, gathering the international experts in these pathologies. Theralis(R) is the new CE Marked fully automated system resulting from Theradiag's research, providing one of the market's most comprehensive multiplex set of assays. Steered by the new Solinium(R) multi-platform software, this new tool incorporates multiplex FIDIS(R), immunofluorescence and ELISA technologies. All of a laboratory's auto-immune analyses can thus be carried out using the same instrument. This new solution is unique on its market. Polyvalent, Theralis(R) enables up to 120 samples and 60 tests to be loaded and 3 analysis methodologies to be carried out simultaneously. Theralis(R) thus meets the demands of public and private laboratories, which need greater polyvalence and speed to cope with their requirements, but also enhanced precision and reliability for patient diagnostics. This new platform further consolidates the multiple Fidis portfolio.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALTER:FP €4.26 EUR +0.09

ALTER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALTER.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALTER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERADIAG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at